Anika Schick

Anika Schick

Auto-generated profile, based on publicly available information

Anika Schick

Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAnika Schick
Anika Schick
MGMarc San Jose Gracia
Marc San Jose Gracia
HHHans Christian D. Hammershøj
Hans Christian D. Hammershøj
JBJohan Broddefalk
Johan Broddefalk
PMPablo Martínez-Pardo
Pablo Martínez-Pardo
Charles S ElmoreCharles S Elmore
Charles S Elmore
Peptides constitute a well-established and rapidly expanding field in the contemporary pharmaceutical drug landscape. Studies with 14 C- or 3 H-radiolabeled analogs are the gold standard for drug development, yet access to 14 C-peptides is costly and limited to derivatization of the native structure with tags or lengthy multi-step syntheses. In this work, we report a platform that installs 14 C- or 3 H-radiolabeled lysine residues directly on solid-supported peptides. The workflow constitutes a mild, peptide-compatible hydroformylation process of allylglycine residues to generate labeled allysine, followed by reductive amination that furnishes radiolabeled lysine residues directly upon cleavage from the solid support. The hydroformylation setup can be tuned for flexible isotope introduction by using 14 CO from solid precursors and 3 H 2 from standard tritium manifolds. We show that the optimized workflow tolerates diverse sequences and enables functionalization of peptides as complex as semaglutide analogs.

1 January 2026 in Organic Chemistry Frontiers
Verified
Journal Article
Open access
ASAnika Schick
Anika Schick
CBChristoph Bauer
Christoph Bauer
TSTove Slagbrand
Tove Slagbrand
MGMichael Guerzoni
Michael Guerzoni
MJMaria Johansson
Maria Johansson
MAMarkus Artelsmair
Markus Artelsmair
We developed a rapid screening protocol based on transfer deuteration using formic acid- d 2 as the deuterium source. These conditions allow rapid screening of up to 96 hydrogen-isotope-exchange reactions in a controlled and safe manner.